Titlebook: Annual Reports in Combinatorial Chemistry and Molecular Diversity; W. H. Moos,M. R. Pavia Book 1999 Springer Science+Business Media Dordre

AVERT

四指套

Patent tactics in molecular diversity: Things that get around, come around,in FDA approval. Exemptions to infringement provided by 35 U.S.C. §271(e)(1) are discussed along with recent cases interpreting this statute. The evolution of the statute in providing an exemption to activities necessary to obtain FDA marketing approval is described to provide background, legislativ

袋鼠

Advances in diversity profiling and combinatorial series design,aries containing hundreds to tens of thousands of compounds, using molecular diversity as a means to design and prioritize experiments. This paper reviews some of the most important computational work in the field of diversity profiling and combinatorial library design, with particular emphasis on m

破譯密碼

Comprehensive survey of chemical libraries yielding enzyme inhibitors, receptor agonists and antagocludes citations as early as 1992, when the first descriptions of biologically active libraries were disclosed, and continues through 1997. Four tables are provided listing libraries screened against (1) proteolytic enzymes, (2) non-proteolytic enzymes, (3) G-protein coupled receptors (GPCRs), and (

grenade

bizarre

Harmonic Oscillator as an Effective Theory,s in the drug discovery process. Solution-phase work is free from some of the constraints of solid-phase approaches but has disadvantages with respect to purification. This article will also illustrate some of the advances made in recent years in solution phase array chemistry including using suppor

遺棄

Effective Training of Arthroscopic Skills has shifted toward smaller, more focused libraries for lead optimization. These focused libraries generally consist of individual discrete compounds. Biological assay requirements often require compounds of high purity, thus development of automated high throughput purification methods has received

LAIR

FLINT

ANIM

Acute Pain Management in Older Adults,in FDA approval. Exemptions to infringement provided by 35 U.S.C. §271(e)(1) are discussed along with recent cases interpreting this statute. The evolution of the statute in providing an exemption to activities necessary to obtain FDA marketing approval is described to provide background, legislativ